

## ORIGINAL ARTICLE / ОРИГИНАЛНИ РАД

# Serum resistin and adiponectin relationships with glucometabolic control in patients with type 2 diabetes mellitus

Khalid A. Al-Regaiey<sup>1</sup>, Syed S. Habib<sup>1</sup>, Laila Al Dokhi<sup>1</sup>, Anwar A. Jammah<sup>2</sup>, Mohammad M. Subhan<sup>3</sup><sup>1</sup>King Saud University, College of Medicine, Department of Physiology, Riyadh, Saudi Arabia;<sup>2</sup>King Saud University, College of Medicine, Department of Medicine, Riyadh, Saudi Arabia;<sup>3</sup>Plymouth University, School of Biomedical and Healthcare Sciences, United Kingdom**SUMMARY**

**Introduction/Objective** Adiponectin and resistin are important adipokines that play an important role in the regulation of blood sugar, beta-oxidation in muscles, and insulin resistance. This study aimed to assess and compare the relationships of resistin and adiponectin concentrations with glucometabolic control in patients with type 2 diabetes mellitus (T2DM).

**Methods** A total of 191 subjects were studied. The final selection included 107 patients with T2DM (67 males and 40 females) and 84 healthy control subjects (45 males and 39 females). Fasting venous blood samples were analyzed for glucose (FBG), glycosylated hemoglobin (HbA1c), insulin, lipids, adiponectin and resistin levels. Body composition was evaluated in all subjects by the body mass index (BMI) and waist-hip ratio (WHR).

**Results** BMI, WHR, FBG, HbA1c, homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol, and triglycerides were significantly higher in individuals with T2DM compared to healthy volunteers. Serum resistin levels were significantly higher ( $p = 0.0259$ ) and serum adiponectin levels were significantly lower ( $p = 0.0001$ ) in T2DM patients than in control subjects. Adiponectin levels were significantly lower ( $p = 0.0411$ ) in diabetes patients with poor glycemic control, compared to those with good glycemic control, while the difference was non-significant for resistin ( $p = 0.8899$ ). Serum adiponectin levels were discordant with HbA1c ( $r = -0.274$ ,  $p = 0.004$ ). Linear-by-linear association showed significant trend of better glycemic control at increasing quartiles of adiponectin levels ( $p = 0.042$ ), while the trend was not significant for resistin levels ( $p = 0.904$ ). Multiple regression analysis revealed FBG, insulin, HOMA-IR, and HbA1c as significant predictors of adiponectin.

**Conclusions** T2DM patients have significantly higher resistin and lower adiponectin levels compared to healthy controls. Adiponectin levels were significantly lower in patients with poor glycemic control.

**Keywords:** adiponectin; resistin; dyslipidemia; type 2 diabetes mellitus

**INTRODUCTION**

It is well known that obesity increases the risk of developing type 2 diabetes mellitus (T2DM) [1]. Adipose tissue is a complex endocrine organ with potential implications on insulin resistance, obesity and diabetes. Many researches have resulted in identification of a large group of adipocyte-specific proteins, such as adiponectin, acylation-stimulating protein, resistin, leptin, which are involved in regulating glucose and lipid metabolism and insulin resistance in obesity and diabetes [1, 2, 3]. Therefore, high visceral fat and insulin resistance have been reported to be independently associated with prediabetes and T2DM [4]. Adipose tissue dysfunction is characterized by ectopic fat deposition in the abdominal viscera and liver, inflammatory and adipokine dysregulation, and insulin resistance, which may be a more important mediator of diabetes development than total fat mass as such [5, 6].

Adipocyte-specific proteins, such as adiponectin, acylation-stimulating protein, resistin and leptin, have recently been identified [7].

Resistin and adiponectin are important adipokines that regulate insulin sensitivity. Adiponectin, synthesized in the adipose tissue, appears to play an important role in inflammatory mechanisms, glycemic and lipid control, which cluster together to markedly increase the atherosclerotic risk in diabetes subjects. Plasma adiponectin concentrations are reported to be decreased in patients with obesity, T2DM, insulin resistance syndromes, dyslipidemia, and coronary artery disease [8–12]. Resistin is secreted by adipocytes and leads to insulin resistance in vivo and in vitro and is considered to be an important link between obesity and diabetes [13].

Lower levels of adiponectin in obese subjects are associated with higher levels of resistin and are considered to contribute to insulin resistance and accelerated atherogenesis [14]. Plasma adiponectin levels correlate negatively with adiposity, and serum adiponectin levels and waist-hip ratio (WHR) are independent predictors of high-sensitivity C-reactive protein levels in normoglycemic subjects [15, 16, 17]. Hence, both adiponectin and resistin have important biological activity on glucose and lipid

**Received • Примљено:**

January 24, 2017

**Revised • Ревизија:**

November 2, 2017

**Accepted • Прихваћено:**

November 7, 2017

**Online first:** November 17, 2017**Correspondence to:**Syed Shahid HABIB  
Department of Physiology (29)  
College of Medicine  
PO Box 2925  
King Saud University  
Riyadh 11461  
Kingdom of Saudi Arabia  
[shahidhabib44@hotmail.com](mailto:shahidhabib44@hotmail.com)

metabolism. However, the comparison of these adipokines on glucometabolic control needs further investigation. Therefore, the aim of this study was to assess and compare the relationships of resistin and adiponectin concentrations with glucometabolic control in patients with T2DM.

## METHODS

This case-control study was carried out at the Department of Physiology and Medicine, College of Medicine, and King Khalid University Hospital, King Saud University, Riyadh. The study was approved by the Institutional Review Board of the College of Medicine. A total of 191 subjects were selected for the study. Final analysis included 107 patients with T2DM (67 males and 40 females). The control group included 84 healthy subjects (45 males and 39 females) matched for age, sex, and weight, recruited from staff members and the patients' companions. All the patients were diagnosed with T2DM based on American Diabetes Association criteria and were in stable metabolic condition with at least one year of duration of T2DM [18]. Patients with acute diabetes states, acute or chronic renal problems, thyroid diseases, acute and chronic infections, stroke, taking oral contraceptives or steroids, were excluded. Clinical and demographic data from all the participants was recorded on a predesigned form, which included weight, height, the body mass index (BMI), WHR measurements, and exercise habits. The patients were divided into a good and a poor glycemic control group based on a cut-off glycosylated hemoglobin (HbA1c) value of 7.5% [18]. After 10–12 hours of overnight fasting, venous blood samples were analyzed for total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL), fasting blood glucose (FBG), HbA1c, basal insulin, adiponectin, and resistin levels. Human insulin, adiponectin, and resistin immunoassays were carried out by quantitative standard sandwich enzyme-linked immunosorbent assay (ELISA) technique using a monoclonal antibody specific for resistin with kits supplied by R&D Systems, (Abingdon, United Kingdom). Insulin resistance was calculated by homeostasis model assessment of insulin resistance (HOMA-IR) using the formula  $HOMA-IR = (FPI \text{ (mU/L)} \times FPG \text{ (mmol/L)}) / 22.5$  [19].

Bioelectrical impedance analysis was used to measure body composition with InBody 3.0 (Biospace Inc., Seoul, Korea) body analyzer according to the manufacturer's instructions. All assessments were made with the respondents being in the early morning fasting state, wearing light clothes, and after emptying of the urinary bladder. The machine calculated the amount of each tissue with the difference in electrical impedance [20].

## Statistical analysis

The data was analyzed by IBM SPSS Statistics for Windows, Version 19.0 (IBM Corp., Armonk, NY, USA). Descriptive characteristics of the study patients were calculated as mean  $\pm$  standard deviation. The tests applied for statistical

analysis were Student's t-test for normally distributed data and Mann-Whitney U-test for skewed data. We applied and used the linear-by-linear association p-value for significant difference at different quartiles of adiponectin and resistin levels in diabetes patients. Spearman's correlations and multiple regression analysis were performed to show the predictors of adiponectin and resistin levels. A p-value of  $< 0.05$  was taken as statistically significant.

## RESULTS

This study reveals relationships between adiponectin and resistin concentrations with glycemic and lipid control in patients with T2DM. Table 1 shows comparison of descriptive characteristics and biochemical profile between control and diabetes patients. BMI, WHR, FBG, HbA1c, HOMA-IR, TC, and TG were significantly higher in individuals with diabetes compared to healthy volunteers. Exercise prevalence in each group was also compared and it was non-significant (Table 1). T2DM patients were divided into good and poor glycemic control group based on a cut-off HbA1c value of 7.5%. Table 2 expresses the comparison of descriptive characteristics and biochemical profile between good and poor glycemic control in T2DM patients. BMI ( $p = 0.0257$ ), HOMA-IR ( $p = 0.0002$ ), and TG ( $p = 0.0006$ ) were significantly higher in the poor glycemic control group than in the good glycemic control group.

Box plot represents serum adiponectin and resistin levels in controls, all subjects with diabetes, and in those with good and poor glycemic control (Figures 1 and 2). Serum resistin levels were significantly higher ( $p = 0.0259$ ) (Figure 1) and serum adiponectin levels significantly lower ( $p = 0.0001$ ) (Figure 2) in T2DM patients than in healthy

**Table 1.** Comparison of descriptive characteristics and biochemical profile between controls and T2DM patients (mean  $\pm$  SD)


Characteristics	Controls n = 84	T2DM n = 107	p
Male/Female	45/39	67/40	/
Age (years)	50.16 $\pm$ 12.58	52.20 $\pm$ 11.07	0.2735
Height (cm)	166.80 $\pm$ 8.52	165.71 $\pm$ 13.93	0.2641
Weight (kg)	77.66 $\pm$ 14.78	84.23 $\pm$ 20.60	0.0515
WHR	0.94 $\pm$ 0.12	1.11 $\pm$ 0.09	0.0001
BMI (kg/m <sup>2</sup> )	28.13 $\pm$ 4.80	29.72 $\pm$ 5.27	0.0227
FBG (mmol/dl)	5.06 $\pm$ 0.99	8.88 $\pm$ 3.29	0.0001
HbA1c (%)	5.01 $\pm$ 0.56	7.67 $\pm$ 1.53	0.0001
Insulin ( $\mu$ U/ml)	22.69 $\pm$ 6.12	24.81 $\pm$ 9.19	0.0708
HOMA-IR	5.20 $\pm$ 2.46	9.73 $\pm$ 5.08	0.0001
TC (mmol/L)	4.25 $\pm$ 0.96	4.48 $\pm$ 1.12	0.0515
TG (mmol/L)	1.41 $\pm$ 1.19	2.04 $\pm$ 1.44	0.0463
LDL (mmol/L)	2.68 $\pm$ 0.86	2.62 $\pm$ 0.91	0.1264
HDL (mmol/L)	1.17 $\pm$ 0.23	1.04 $\pm$ 0.31	0.1020
TC (mmol/L)	4.25 $\pm$ 0.96	4.48 $\pm$ 1.12	0.0515
Exercise n (%)			
No	45 (42.66)	52 (54.34)	0.4949
Yes	39 (41.34)	55 (52.66)	

BMI – body mass index; WHR – waist-hip ratio; FBG – fasting blood glucose; HbA1c – glycosylated hemoglobin; TC – total cholesterol; TG – triglycerides; LDL – low-density lipoprotein; HDL – high-density lipoprotein


**Table 2.** Comparison of descriptive characteristics and biochemical profile between good and poor glycemic control in T2DM patients (mean ± SD)

Characteristics	HbA1c < 7.5 n = 50	HbA1c ≥ 7.5 n = 57	p
Male/Female	28/22	30/27	
Age (years)	53.90 ± 10.51	51.32 ± 11.15	0.2283
Height (cm)	167.63 ± 6.01	164.48 ± 17.53	0.2474
Weight (kg)	79.94 ± 15.10	84.78 ± 17.17	0.1342
WHR	0.99 ± 0.07	1.01 ± 0.09	0.1613
BMI (kg/m <sup>2</sup> )	28.46 ± 4.97	30.77 ± 5.26	0.0257
FBG (mmol/dl)	7.10 ± 1.64	10.20 ± 3.61	0.0001
HbA1c (%)	6.58 ± 0.44	9.66 ± 2.58	0.0001
Insulin (µU/ml)	23.91 ± 7.51	25.24 ± 10.68	0.4705
HOMA-IR	7.66 ± 3.47	11.19 ± 5.49	0.0002
TC (mmol/L)	4.19 ± 0.84	4.58 ± 1.26	0.1279
TG (mmol/L)	1.47 ± 0.69	2.36 ± 1.30	0.0006
LDL (mmol/L)	2.54 ± 0.85	2.75 ± 0.93	0.3307
HDL (mmol/L)	1.00 ± 0.24	1.08 ± 0.49	0.3783


BMI – body mass index; WHR – waist–hip ratio; FBS – fasting blood glucose; HbA1c – glycosylated hemoglobin; TC – total cholesterol; TG – triglycerides; LDL – low-density lipoprotein; HDL – high-density lipoprotein




**Figure 1.** Comparison of adiponectin levels between control subjects, all patients with type 2 diabetes mellitus, and those with good (HbA1c < 7.5) and poor glycemic control (HbA1c ≥ 7.5)



**Figure 2.** Comparison of resistin levels between controls, all patients with type 2 diabetes mellitus, and those with good (HbA1c < 7.5) and poor glycemic control (HbA1c ≥ 7.5)



**Figure 3.** Scatter plot showing the association of circulating levels of adiponectin (a) and resistin (b) with glycosylated hemoglobin (HbA1c)



**Figure 4.** Linear-by-linear association of HbA1c% at different quartiles of adiponectin and resistin levels in diabetes patients; there is a significant trend of better glycemic control at increasing levels of adiponectin levels (p = 0.042), while the trend was not significant for resistin levels (p = 0.904)

subjects. We observed that serum adiponectin levels were significantly lower (p = 0.0411) in diabetes patients with poor glycemic control, compared to those with good glycemic control, but the difference was non-significant for resistin (p = 0.8899). Scatter plot in Figure 3 shows the relationship of adiponectin (a) and resistin (b) with glycemic control. Serum adiponectin levels were discordant with HbA1c (r = -0.274, p = 0.004). No relationship between HbA1c and resistin levels was observed (r = 0.017, p = 0.866). Linear-by-linear association of HbA1c% at different quartiles of adiponectin and resistin levels in diabetes patients was also determined. There was a significant trend of better glycemic control at increasing levels of adiponectin levels (p = 0.042), while the trend was not significant for resistin levels (p = 0.904), which was depicted by linear-by-linear association of HbA1c% at different quartiles of adiponectin and resistin levels in diabetes patients as shown in Figure 4.

Multiple regression analysis was performed keeping adiponectin and resistin as dependent variables to determine their predictive factors (Table 3). Significant predictors of adiponectin levels were FBS, insulin, HOMA-IR, and HbA1c. For resistin, none of the variables was significant. Table 4 expresses the proportion of patients using medications for diabetes and comorbidities in patients with T2DM.

**DISCUSSION**

The present study aims to assess and compare the relationships of resistin and adiponectin concentrations with

**Table 3.** Multiple regression analysis for prediction of adiponectin and resistin levels in T2DM patients

Parameter	Adiponectin (ng/ml) Standardized Beta Coefficients	p	Resistin (ng/ml) Standardized Beta Coefficients	p
FBS (mmol/L)	1.498	0.015	0.481	0.507
Insulin ( $\mu$ U/ml)	1.524	0.018	0.518	0.493
HOMA-IR	-2.317	0.016	-0.855	0.450
HbA1c (%)	-0.237	0.014	0.284	0.182
TG (mmol/L)	-0.150	0.315	-0.201	0.268
TC (mmol/L)	-0.260	0.122	0.153	0.448
HDL (mmol/L)	0.074	0.618	-0.089	0.620
LDL (mmol/L)	0.133	0.472	-0.401	0.079
Duration (years)	0.268	0.063	-0.186	0.283

BMI – body mass index; WHR – waist-hip ratio; FBS – fasting blood glucose; HbA1c – glycosylated hemoglobin; TC – total cholesterol; TG – triglycerides; LDL – low-density lipoprotein; HDL – high-density lipoprotein

**Table 4.** Use of medications for diabetes and comorbidities in patients with T2DM

Medicines for diabetes	n (%)
Biguanides	14 (13.1)
Sulphonylureas	25 (23.4)
Glinides	11 (10.3)
Alpha-glucosidase inhibitors	21 (11.2)
Thiazolidinedione	23 (21.5)
Lipid-lowering medicines	25 (23.4)

glycemic and lipid control in patients with T2DM. We observed that T2DM patients have significantly higher resistin and lower adiponectin levels. The effect of glycemic control on resistin levels was not significant. However, adiponectin was significantly lower in patients with poor glycemic control, compared to those with good glycemic control. Similar to a report by Schulze et al. [21], our study supports the hypothesis that increased adiponectin levels might be associated with better lipid and glycemic control with reduced inflammation in patients with T2DM. Measures that could increase adiponectin levels might be valuable targets for decreasing the higher coronary artery disease risk in diabetes.

In another similar study, adiponectin was found to be significantly decreased in T2DM patients as compared to normal control subjects. Adiponectin levels were negatively associated with high-sensitivity C-reactive protein, LDL-C, HbA1c, TG, TC, and positively with HDL-C. HbA1c had a negative correlation with serum adiponectin. This shows that adiponectin may play an important role in the pathogenesis of diabetes, and may emerge as an independent predictor of the development of T2DM [22]. Nayak et al. [23] showed that adiponectin decreases with increasing adiposity and insulin resistance regardless of diabetes status. Among non-obese subjects, adiponectin correlated negatively with TG, interleukin-6, and HOMA-IR, and correlated positively with HDL. Diabetes status, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), and BMI were identified as independent predictors of adiponectin. Glucose and adiponectin were useful indicators of T2DM. Moreover,

insulin-mediated glucose turnover was significantly affected by adiponectin and TNF- $\alpha$  [23]. Adiponectin negatively correlated with BMI after adjusting for age, sex, and diabetes status [24]. In an interesting study, Lau et al. [25] proposed a novel adiponectin-resistin (AR) index by taking into account both adiponectin and resistin levels to provide a better indicator of the metabolic homeostasis and metabolic disorders. A novel insulin resistance (IRAR) index was derived to provide an improved diagnostic biomarker of insulin sensitivity.

Adipocytokines that have been implicated in the pathogenesis of metabolic syndrome include TNF- $\alpha$ , interleukin-6, angiotensinogen, leptin, plasminogen activator inhibitor-1, and resistin [26]. The present study supports the evidence that resistin plays an important role in the pathogenesis of obesity and insulin resistance. We reported previously that higher resistin levels in T2DM have a significant positive correlation with body fat mass [27]. However, in the present study, although T2DM patients had higher resistin levels, the effect of glycemic control on resistin levels was not significant. In a study on Chinese T2DM patients, 16 weeks of liraglutide administration led to increased adiponectin and decreased resistin levels compared to glimepiride-treated subjects, while inducing similar glycemic changes [28]. Adiponectin, leptin, and resistin levels are affected by the use of anti-diabetes drugs among which glimepiride shows more effect on adiponectin and resistin levels, while leptin gets affected more by metformin. It shows that the adipokine levels are not affected by diabetes only, suggesting that their alterations in T2DM may be due to obesity. Therefore, there might be important links between adiposity and insulin resistance [29].

The limitation of the present work is its cross-sectional design and small sample size. We recommend further large-scale prospective studies to additionally explore the true homeostatic roles of adiponectin and resistin in patients with T2DM. Since they are related to glucose and lipid metabolism, it would be worth studying them as an integrated approach in relation to different pharmacological interventions and physical fitness programs. They may prove to be useful integrated biomarkers to predict metabolic dysregulation and cardiovascular risk in T2DM.

## CONCLUSION

T2DM patients have significantly higher resistin and lower adiponectin levels when compared to healthy controls. Adiponectin levels were significantly lower in patients with poor glycemic control. However, the effect of glycemic control on resistin levels was not significant.

## ACKNOWLEDGMENT

The authors are thankful to Dr. Shaikh Mujeeb Ahmed and Mr. James Chu for collection of data and blood assays. We are thankful to King Abdul Aziz City for Science and Technology for supporting this project (Project No. 26-60).

## REFERENCES

- Jensen MD. Role of body fat distribution and the metabolic complications of obesity. *J Clin Endocrinol Metab.* 2008; 93(11 Suppl 1):S57–63.
- Ahima RS. Central actions of adipocyte hormones. *Trends Endocrinol Metab* 2005; 16(7): 307–13.
- Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. *Biochem Cell Biol.* 2004; 82(1):170–90.
- Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. *JAMA.* 2012; 308(11):1150–9.
- McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. *J Clin Endocrinol Metab.* 2011; 96(11):E1756–60.
- Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham Heart Study. *Obesity (Silver Spring).* 2010; 18(11):2191–8.
- Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. *Biochem Cell Biol.* 2004; 82(1):170–90.
- Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. *Biochem Biophys Res Commun.* 2012; 425(3):560–4.
- Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol.* 2000; 20(6):1595–9.
- Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Platley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab.* 2001; 86(5):1930–5.
- Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. *J Clin Endocrinol Metab.* 2002; 87(6):2764–9.
- Nanayakkara G, Kariharan T, Wang L, Zhong J, Amin R. The cardio-protective signaling and mechanisms of adiponectin. *Am J Cardiovasc Dis.* 2012; 2(4):253–66.
- Flier JS. Diabetes. The missing link with obesity? *Nature.* 2001; 409(6818):292–3.
- Beltowski J. Adiponectin and resistin – new hormones of white adipose tissue. *Med Sci Monit.* 2003; 9(2):RA55–61.
- Habib SS, Al Regaiey KA, Al Dokhi L. Assessment of adipokines relationships with cardiovascular risk Markers in relation to body indices in normoglycemic males. *Pak J Med Sci.* 2013; 29(1):21–6.
- Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K, et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. *Obes Res.* 2003; 11(9):1072–9.
- Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arkan S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? *J Endocrinol Invest.* 2007; 30(3):210–4.
- American Diabetes Association. Standards of medical care in diabetes – 2010. *Diabetes Care.* 2010; 33 Suppl 1:S11–61.
- Singh B, Saxena A. Surrogate markers of insulin resistance: A review. *World J Diabetes.* 2010; 15; 1(2):36–47.
- Boneva-Asiova Z, Boyanov MA. Body composition analysis by leg-to-leg bioelectrical impedance and dual-energy X-ray absorptiometry in non-obese and obese individuals. *Diabetes Obes Metabol.* 2008; 10(11):1012–8.
- Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. *Diabetes Care.* 2004; 27(7):1680–7.
- Goodarzi MT, Babaahmadi-Rezaei H, Kadkhodaei-Eliaderani M, Haddadinezhad S. Relationship of serum adiponectin with blood lipids, HbA(1)c, and hs-CRP in type II diabetic postmenopausal women. *J Clin Lab Anal.* 2007; 21(3):197–200.
- Nayak BS, Ramsingh D, Gooding S, Legall G, Bissram S, Mohammed A, et al. Plasma adiponectin levels are related to obesity, inflammation, blood lipids and insulin in type 2 diabetic and non-diabetic Trinidadians. *Prim Care Diabetes.* 2010; 4(3):187–92.
- Nayak S, Soon SQ, Kunjal R, Ramadoo R, Baptiste O, Persad J, et al. Relationship between adiponectin, inflammatory markers and obesity in type 2 diabetic and non-diabetic Trinidadians. *Arch Physiol Biochem.* 2009; 115(1):28–33.
- Lau CH, Muniandy S. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. *Cardiovasc Diabetol.* 2011; 10(1):8.
- Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. *Clin Sci (Lond).* 2005; 109(3):243–56.
- Habib SS. Serum resistin levels in patients with type 2 diabetes mellitus and its relationship with body composition. *Saudi Med J.* 2012; 33(5):495–9.
- Li D, Xu X, Zhang Y, Zhu J, Ye L, Lee KO, et al. Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes. *Diabetes Res Clin Pract.* 2015; 110(2):224–8.
- Farooq R, Amin S, Hayat Bhat M, Malik R, Wani HA, Majid S. Type 2 diabetes and metabolic syndrome - adipokine levels and effect of drugs. *Gynecol Endocrinol.* 2017; 33(1):75–8.

## Однос серумског резистина и адипонектина и глукометаболичка контрола код болесника са дијабетесом мелитусом типа 2

Халид А. ел Регаиеј<sup>1</sup>, Сајед Ш. Хабиб<sup>1</sup>, Лејла ел Дохи<sup>1</sup>, Анвар А. Џамах<sup>2</sup>, Мохамед М. Субхан<sup>3</sup>

<sup>1</sup>Универзитет краља Сауда, Медицински колеџ, Катедра за физиологију, Ријад, Саудијска Арабија;

<sup>2</sup>Универзитет краља Сауда, Медицински колеџ, Катедра за медицину, Ријад, Саудијска Арабија;

<sup>3</sup>Универзитет у Плимуту, Факултет биомедицинских и здравствених наука, Плимут, Велика Британија

### САЖЕТАК

**Увод/Циљ** Адипонектин и резистин су адипокини који играју важну улогу у регулисању шећера у крви, бета-оксидацији у мишићима и инсулинској резистенцији.

Циљ ове студије је био да процени и упореди односе концентрација резистина и адипонектина са глукометаболичком контролом код болесника са шећерном болешћу типа 2 (ШБТ2).

**Метод** Испитан је укупно 191 испитаник. Коначна селекција обухватила је 107 болесника са ШБТ2 (67 мушкараца и 40 жена) и 84 здравих, контролних особа (45 мушкараца и 39 жена). Анализирани су узорци венске крви за глукозу (ВГ), гликозиловани хемоглобин (*HbA1c*), инсулин, липиди (укупни холестерол – УХ, триглицериди – ТГ), адипонектин и резистин. Грађа тела оцењена је код свих и то индексом телесне масе (ИТМ) и односом струк–кукови (ОСК).

**Резултати:** ИТМ, ОСК, ВГ, *HbA1c*, инсулинска резистенција (ИР), УХ и ТГ били су значајно већи код особа с дијабетесом у поређењу са здравим добровољцима. Ниво резистина у

серуму био је значајно виши ( $p = 0,0259$ ), а ниво серумског адипонектина значајно нижи ( $p = 0,0001$ ) код ШБТ2 него код контролних субјеката. Ниво адипонектина били су значајно нижи ( $p = 0,0411$ ) код болесника са лошом контролом гликемије у поређењу са онима са добром гликемијском контролом, док је разлика нивоа резистина била безначајна ( $p = 0,8899$ ). Ниво адипонектина у серуму нису у корелацији са *HbA1c* ( $p = -0,274$ ,  $p = 0,004$ ). Линеарна корелација показала је значајан тренд боље контроле гликемије код повећања нивоа адипонектина ( $p = 0,042$ ), док тренд није био значајан за нивое резистина ( $p = 0,904$ ). Мултипла регресиона анализа открила је ВГ, инсулин, ИР и *HbA1c* као значајне предикторе адипонектина.

**Закључак:** Болесници са ШБТ2 имају знатно повишен резистен и снижен адипонектин у поређењу са здравим особама. Ниво адипонектина су знатно нижи код болесника са slabом контролом гликемије.

**Кључне речи:** адипонектин; резистин; дислипидемија; шећерна болест тип 2